Kristina Kovaleva

Dr. Kristina Kovaleva

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2025 in Vestnik
Verified
Journal Article
Closed access
ZTZ.B. Tileules
Z.B. Tileules
ATA. Tolegenkyzy
A. Tolegenkyzy
ZAZhanar Akhmetova
Zhanar Akhmetova
KKKristina Kovaleva
Kristina Kovaleva
GBG.S. Bismildina
G.S. Bismildina
ZKZulfiya Kachiyeva
Zulfiya Kachiyeva
Introduction. Atopic dermatitis belongs to a group of allergic diseases, including food allergies, allergic rhinitis, and asthma. Atopic dermatitis is a common chronic heterogeneous inflammatory skin disease characterized by relapses. The main factors contributing to its development include genetic predisposition, epidermal barrier disruption, and immune system dysfunction. The aim of this study is to investigate the polymorphisms of atopic dermatitis genes among the population of Kazakhstan. Materials and methods.Our case-control study involved 322 people with atopic dermatitis and 328 healthy controls. 120 SNPs were selected and genotyped using a Quant Studio 12K Flex real-time PCR system. Results.Significant associations were identified between eight single nucleotide polymorphisms (SNPs) (rs79497729, rs12144049, rs2321443, rs3091307, rs3208007, rs10995245, rs56302621, rs72823628) and atopic dermatitis. Conclusion. Our data confirm and expand the current understanding of the influence of SNPs on atopic dermatitis. Importantly, this study is unique in focusing on the Kazakhstani population, providing valuable insights into Central Asia, where research data are scarce or absent for this region. Кірспе. Атопиялық дерматит тағамдық аллергия, аллергиялық ринит және астма сияқты аллергиялық аурулар тобына жатады. Атопиялық дерматит рецидивтермен сипатталатын кең таралған созылмалы гетерогенді қабынатын тері ауруы. Оның дамуына ықпал ететін негізгі факторлар – генетикалық бейімділік, эпидермиялық барьердің бұзылуы және иммундық жүйенің дисфункциясы. Бұл зерттеудің мақсаты Қазақстан тұрғындары арасында атопиялық дерматит гендерінің полиморфизмін зерттеу. Материалдар мен әдістер. Біздің жағдайда, зерттеуге атопиялық дерматитпен ауыратын 322 адам және 328 сау бақылау тобы қатысты. Барлығы 120 бірнуклеотидтік полиморфизм (SNP) Quant Studio 12K Flex нақты уақыттағы ПТР жүйесі арқылы скринингтен өтті және генотиптелді. Нәтижелер. Сегіз SNP (rs79497729, rs12144049, rs2321443, rs3091307, rs3208007, rs10995245, rs56302621, rs72823628) және атопиялық дерматит арасында маңызды байланыстар анықталды. Қорытынды. Біздің деректеріміз атопиялық дерматитте SNP әсерінің қазіргі түсінігін растайды және кеңейтеді. Зерттеу маңызын атап өтсек, зерттеу Қазақстан популяциясының ерекшеліктеріне назар аударуымен ерекшеленеді және зерттеу мәліметтері аз немесе мүлдем жоқ Орталық Азия жөнінде құнды ақпарат береді. Введение.Атопический дерматит относится к группе аллергических заболеваний, включая пищевую аллергию, аллергический ринит и астму. Атопический дерматит – распространенное хроническое гетерогенное воспалительное заболевание кожи, характеризующееся рецидивами. Основными факторами, способствующими его развитию, являются генетическая предрасположенность, нарушение эпидермального барьера и дисфункция иммунной системы. Целью данного исследования является изучение полиморфизма генов атопического дерматита среди населения Казахстана. Материалы и методы. В нашем исследовании случай-контроль приняли участие 322 человека с атопическим дерматитом и 328 здоровых лиц. Было отобрано и генотипировано 120 однонуклеотидных полиморфизмов (SNP) с использованием системы ПЦР в реальном времени Quant Studio 12K Flex. Результаты. Значимые ассоциации были выявлены между восемью SNP (rs79497729, rs12144049, rs2321443, rs3091307, rs3208007, rs10995245, rs56302621, rs72823628) и атопическим дерматитом. Заключение. Наши данные подтверждают и расширяют текущее понимание влияния SNP на атопический дерматит. Важно отметить, что это исследование уникально тем, что фокусируется на популяции Казахстана, предоставляя ценную информацию о Центральной Азии, где данные исследований скудны или отсутствуют для этого региона.

19 November 2025 in Genes
Verified
Journal Article
Open access
PDF file
ZIZhannat Idrissova
Zhannat Idrissova
Farida RakhimbekovaFarida Rakhimbekova
Farida Rakhimbekova
MOMadina Orazgaliyeva
Madina Orazgaliyeva
MZMadina Zhaksybek
Madina Zhaksybek
KKKristina Kovaleva
Kristina Kovaleva
PVPetr Vasiluev
Petr Vasiluev
Background/Objectives: This study presents the first molecular characterization of NF1 gene variants in Kazakhstani patients, expanding regional understanding of neurofibromatosis type 1 (NF1). The NF1 gene encodes neurofibromin, a tumor suppressor protein that regulates the MAPK signaling pathway; its inactivation results in NF1, a multisystem disorder with pigmentary and tumor manifestations. Methods: A total of 60 pediatric and young adult patients of University Clinic Aksai were selected based on Legius criteria and studied clinically; genetic variants of NF1 gene were determined with AmpliSeq for Illumina Myeloid Panel (next generation sequencing). Results: Pathogenic or likely pathogenic (with some variants of unknown significance) were detected in 58 of 60 (96.7%) patients. Among them, 27 (46.6%) carried point variants, 21 (36.2%) had genomic deletions, 3 (5.2%) had duplications, 3 (5.2%) insertions, and 4 (6.9%) had exon–intron splicing site variants. Notably, all patients with duplication insertions and splicing variants presented with plexiform neurofibromas. Conclusions: The study defines the first variant spectrum in a Kazakhstani population, confirming genotype–phenotype correlations consistent with European cohorts (l.). These data highlight the predominance of structural and splicing alterations in patients with plexiform neurofibromas and support the integration of molecular testing into clinical management of NF1 in Kazakhstan.

21 July 2026 in Life
Verified
Journal Article
Open access
PDF file
AAArailym Abilbayeva
Arailym Abilbayeva
Elmira Zheniskhanovna BitanovaElmira Zheniskhanovna Bitanova
Elmira Zheniskhanovna Bitanova
IIIskander Isgandarov
Iskander Isgandarov
БББейбитгуль Бижигитова
Бейбитгуль Бижигитова
DYDinara Yelyubayeva
Dinara Yelyubayeva
NBNishankul Seitbekovna Bozhbanbayeva
Nishankul Seitbekovna Bozhbanbayeva
Introduction: Bronchopulmonary dysplasia (BPD) remains the most significant complication of extreme prematurity, affecting long-term respiratory outcomes. Because current diagnostic criteria identify only established lesions at 36 weeks postmenstrual age, early non-invasive biomarkers are needed. This pilot study aimed to identify a candidate salivary miRNA panel associated with BPD risk and to explore its pathogenetic relevance through in silico analysis. Methods: Saliva was collected from 20 preterm infants (10 with BPD and 10 controls), and miRNA expression was profiled using the GeneChip™ miRNA 4.1 Array Plate. Discriminatory performance was explored by ROC analysis within this discovery cohort, together with power and Spearman correlation analyses. Results: Expression of hsa-let-7b-5p, hsa-let-7c-5p, and hsa-miR-4454 was significantly elevated in the BPD group (p < 0.05, log2FC ≥ 1.0), with no significant correlation with gestational age or birth weight. Bootstrap-corrected AUC values ranged from 0.905 to 0.937 and were supported by leave-one-out cross-validation. All three miRNAs showed very large effect sizes exceeding the minimum detectable effect at 80% power. Conclusions: In this pilot study, salivary miRNAs represent a hypothesis-generating candidate biomarker signal for BPD that requires external validation in larger, independent cohorts before any diagnostic or prognostic application can be considered.